Dr. Jenna Rossoff, MD
Claim this profileLurie Children's Hospital-Chicago
Studies Acute Myeloid Leukemia
Studies Acute Myelogenous Leukemia
10 reported clinical trials
23 drugs studied
Area of expertise
1Acute Myeloid Leukemia
FLT3 positive
CD123 positive
2Acute Myelogenous Leukemia
FLT3 positive
Affiliated Hospitals
Clinical Trials Jenna Rossoff, MD is currently running
CPX-351 + Gilteritinib
for Acute Myeloid Leukemia
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone.
Recruiting2 awards Phase 3
Diagnostic Testing
for Pediatric Leukemia
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Recruiting1 award Phase 1 & 211 criteria
More about Jenna Rossoff, MD
Clinical Trial Related4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Jenna Rossoff, MD has experience with
- IDEAL2 Intervention
- Tagraxofusp
- Flotetuzumab
- CPX-351
- Gilteritinib Fumarate
- Ponatinib
Breakdown of trials Jenna Rossoff, MD has run
Acute Myeloid Leukemia
Acute Myelogenous Leukemia
Leukemia
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jenna Rossoff, MD specialize in?
Jenna Rossoff, MD focuses on Acute Myeloid Leukemia and Acute Myelogenous Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved FLT3 positive patients, or patients who are CD123 positive.
Is Jenna Rossoff, MD currently recruiting for clinical trials?
Yes, Jenna Rossoff, MD is currently recruiting for 6 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Jenna Rossoff, MD has studied deeply?
Yes, Jenna Rossoff, MD has studied treatments such as IDEAL2 Intervention, Tagraxofusp, Flotetuzumab.
What is the best way to schedule an appointment with Jenna Rossoff, MD?
Apply for one of the trials that Jenna Rossoff, MD is conducting.
What is the office address of Jenna Rossoff, MD?
The office of Jenna Rossoff, MD is located at: Lurie Children's Hospital-Chicago, Chicago, Illinois 60611 United States. This is the address for their practice at the Lurie Children's Hospital-Chicago.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.